{"entity":{"id":"nct05944237","kind":"trial","name":"HTL0039732 in Participants With Advanced Solid Tumours","aka":[],"tldr":"A phase 1/2 trial in pancreatic cancer, run by Cancer Research UK, now recruiting.","summary":"HTL0039732 in Participants With Advanced Solid Tumours is a phase 1/2, interventional study registered as NCT05944237 by Cancer Research UK, with a registry enrolment figure of 150 participants, started 2023-07-13 and due to reach its primary completion in 2027-06. Interventions recorded: HTL0039732 Capsules; HTL0039732 Capsules and atezolizumab infusion. Conditions listed: Neoplasms; Prostatic Neoplasms, Castration-Resistant; Stomach Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Colorectal Neoplasms; Pancreatic Neoplasms; Lung Neoplasms; Urinary Bladder Neoplasms; Mesothelioma, Malignant; Uterine Cervical Neoplasms; Kidney Neoplasms; Sarcoma; Pheochromocytomas. Primary outcome: Maximum tolerated dose (MTD; Dose Escalation Phase); RP2D (Dose Escalation Phase); Number of Adverse Events (AEs) Related to HTL0039732 (Dose Escalation and Expansion Phase). Pancreatic eligibility wording from the registry: \"\\- Histologically proven advanced solid tumour where PGE2/EP4 signalling is believed to be more prevalent or significant (such as microsatellite stable colorectal cancer (MSS CRC), gastro-esophageal cancer, head and neck squamous cell carcinoma (HNSCC), mCRPC, pancreatic cancer, lung cancer, bladder\". Sites: United Kingdom. United Kingdom sites listed: 5. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05944237","url":"https://clinicaltrials.gov/study/NCT05944237"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["UK sites (registry): Addenbrooke's Hospital (Cambridge); Velindre Cancer Centre (Cardiff); Clatterbridge Cancer Centre (Liverpool); Guy's Hospital (London); The Christie Hospital (Manchester)."],"nct":"NCT05944237","phase":"1/2","setting":"A Cancer Research UK Phase I/IIa Trial of HTL0039732, Given Orally as Monotherapy and in Combination With Immunotherapy or Other Approved Therapies in Participants With Advanced Solid Tumours","sponsor":"Cancer Research UK","enrolled":150,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05944237/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}